Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Articles published by Faeth Therapeutics

Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer
From Faeth Therapeutics
Via Business Wire
ESMO 2025: Faeth Therapeutics’ Phase 2 DICE Trial Shows 34% Reduction in Risk of Disease Progression with Oral Sapanisertib Plus Chemotherapy
From Faeth Therapeutics
Via Business Wire
Faeth Therapeutics’ R&D Platform Delivers First Cross-Disease Validation Beyond Oncology
From Faeth Therapeutics
Via Business Wire
Faeth Therapeutics Announces Late-Breaking Presentation of Positive Phase 2 Data in Ovarian Cancer at ESMO 2025
From Faeth Therapeutics
Via Business Wire
Faeth Therapeutics Shows Preclinical Proof-of-Concept for Drug-Diet Combination to Treat Cancer, in Peer-Reviewed Publication
From Faeth Therapeutics
Via Business Wire
Faeth Therapeutics and The GOG Foundation, Inc. (GOG-F) Launch First Phase 2 Combination Trial for Sapanisertib-Serabelisib in Patients With Endometrial Cancer
From Faeth Therapeutics
Via Business Wire
Faeth Therapeutics Appoints Dr. Stephen Hahn and Dr. Jayson Dallas to Board of Directors
From Faeth Therapeutics
Via Business Wire
Faeth Therapeutics to Present at Raymond James Biotech Private Company Showcase
From Faeth Therapeutics
Via Business Wire
Faeth Therapeutics to Participate in Upcoming Jefferies Investor Conference
From Faeth Therapeutics
Via Business Wire
Faeth Therapeutics to Participate in the Stifel 2023 Healthcare Conference
From Faeth Therapeutics
Via Business Wire
Faeth Therapeutics Announces National Academy of Medicine Recognition for Co-founder Dr. Siddhartha Mukherjee
From Faeth Therapeutics
Via Business Wire
Faeth Therapeutics Appoints Debbie Chirnomas, M.D., M.P.H., as Chief Medical Officer
From Faeth Therapeutics
Via Business Wire
Faeth Therapeutics Expands Leadership Team with Thomas Strack as Chief Medical Officer and Virginia Casadas as Head of Clinical Operations
From Faeth Therapeutics
Via Business Wire
Faeth Therapeutics Raises $20M to Advance Precision Nutrition Platform as A New Modality in Cancer Treatment
From Faeth Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.